Table 4.
Effect of Hashimoto's disease on chemokine levels: CCL27/CTACK: chemokine ligand 3/monocyte chemoattractant protein-1; CCL3/MIP-1-α: chemokine ligands 3/macrophage inflammatory protein1-alpha; CCL4/MIP-1 β: chemokine ligands 4/macrophage inflammatory protein1 β; β -NGF: β-nerve growth factor; CCL5/RANTES: chemokine ligand 5/regulated on activation, normal T cell expressed and secreted; SCF: stem cell factor; SCGF-β: stem cell growth factor-β; CCL7/MCP-3: chemokine ligand 7/monocyte-chemotactic protein 3; CCL11/eotaxin: chemokine ligand 11/eatoksin; CCL27/CTACK: chemokine ligand 27/cutaneous T cell-attracting chemokine; CXCL1/GRO-α: chemokine (C-X-C motif) ligand 1/growth-regulated oncogene-alpha; CXCL9/MIG: chemokine (C-X-C motif) ligand 9/monokine induced by gamma interferon; CXCL10/IP-10: chemokine (C-X-C motif) ligand 10/interferon gamma-induced protein 10; LIF: leukemia inhibitory factor; CXCL12/SDF-1 α: chemokine (C-X-C motif) ligand 12/stromal cell-derived factor 1; ND: no detectable.
| Saliva | Plasma | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control group | Study group | p value | Control group | Study group | p value | |||||
| Mean ± SD | Median (min-max) | Mean ± SD | Median (min-max) | Mean ± SD | Median (min-max) | Mean ± SD | Median (min-max) | |||
| CCL27/CTACK | 17.80 ± 5.689 | 18.08 (8.970-33.69) | 21.23 ± 6.034 | 20.27 (11.53-36.62) | 0.0195 | 70.22 ± 15.1 | 72.93 (39.18-111.6) | 141.2 ± 71.73 | 128.3 (60-375.5) | <0.0001 |
| CXCL1/Gro-α | 8545 ± 3904 | 8235 (1768 -15622) | 14898 ± 6761 | 15456 (3393-30180) | 0.0005 | 17772 ± 7093 | 18731 (3763-33741) | 19882 ± 7155 | 21785 (4134-29760) | 0.2092 |
| CCL2/MCP-1 | 703 ± 360.5 | 707.8 (198-1490) | 727.7 ± 618.5 | 677 (24.52-2896) | 0.7583 | 4.51 ± 2.51 | 4.557 (0.2395-9.026) | 7.915 ± 4.844 | 5.865 (1.748-19.22) | 0.0189 |
| CCL3/MIP-1α | 33.89 ± 22.89 | 28 (5.895-118.5) | 44.79 ± 67.19 | 28 (7.238-354) | 0.7914 | 123.6 ± 71.94 | 120.1 (11.45-268.1) | 141.2 ± 92.17 | 141.4 (5.762-375.2) | 0.5768 |
| CCL4/MIP-1β | 63.07 ± 26.34 | 54.5 (27.5-138) | 61.73 ± 31.01 | 63 (2.401-129.5) | 0.8362 | 124 ± 79.66 | 117 (16.15-276.7) | 136.5 ± 87.9 | 140.4 (16.26-332.6) | 0.6721 |
| β-NGF | 62.03 ± 23.58 | 66 (8.513-116.3) | 70.33 ± 36.36 | 61 (8.457-143.3) | 0.4973 | 84.27 ± 48.49 | 82.24 (6.667-179.1) | 103.6 ± 52.8 | 99.81 (33.11-275.2) | 0.263 |
| CCL5/RANTES | 2.94 ± 1.038 | 2.927 (0.394-4.531) | 3.48 ± 1.46 | 3.201 (1.084-6.698) | 0.2218 | 1550 ± 620.2 | 1470 (519.6-2704) | 1978 ± 915.4 | 1740 (465.3-4047) | 0.0916 |
| SCF | 77.67 ± 39.69 | 72 (5.96-150) | 89.36 ± 79.58 | 76 (6.221-314) | 0.7914 | 32.98 ± 9.754 | 33.06 (17.22-50.29) | 57.39 ± 19.22 | 55.61 (27.62-89.57) | <0.0001 |
| SCGF-β | 63.07 ± 26.34 | 54.5 (27.5-138) | 61.73 ± 31.01 | 63 (2.401-129.5) | 0.8362 | 539.4 ± 316.7 | 560.9 (43.81-1213) | 660.2 ± 270.4 | 658.4 (150.4-1260) | 0.2467 |
| CCL7/MCP-3 | 18.04 ± 5.184 | 18 (9.874-30) | 20.1 ± 5.504 | 19.5 (10.93-30.9) | 0.1931 | 639.5 ± 136.9 | 619.5 (275.5-879.5) | 697.3 ± 195.3 | 731.6 (206.5-952.3) | 0.1077 |
| CCL11/Eotaxin | 20.05 ± 6.526 | 19.99 (8.792-37.74) | 21.89 ± 9.195 | 18.03 (9.54-43.23) | 0.8475 | 72.15 ± 22.91 | 68.86 (15.32-120.1) | 82.09 ± 32.24 | 75.98 (39.9-159.7) | 0.441 |
| CXCL9/MIG | 608.7 ± 655.1 | 333.5 (17.5-3001) | 1090 ± 1552 | 542.5 (74.97-7798) | 0.3254 | 101.1 ± 92.73 | 68.06 (4.366-413.3) | 133.7 ± 72.15 | 144 (18.91-307.8) | 0.0568 |
| CXCL10/IP-10 | 6686 ± 3147 | 6608 (1730-12452) | 9053 ± 5665 | 7868 (833.7-23044) | 0.1954 | 566.8 ± 346.5 | 542 (12.02-1490) | 742.9 ± 648.9 | 574. (12.51-2896) | 0.444 |
| LIF | 20.42 ± 10.76 | 19 (2.161-45.5) | 25.68 ± 13.15 | 23 (8.214-53.5) | 0.2329 | 24.86 ± 9.771 | 24.31 (9.054-42.78) | 35.38 ± 16.87 | 35.87 (2.65-71.33) | 0.0066 |
| CXCL12/SDF-1α | 53.34 ± 18.2 | 55 (17.55-91.5) | 56.4 ± 22.92 | 53.48 (13.95-101) | 0.6756 | ND | ND | ND | ND | ND |